Literature DB >> 4028623

Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.

H C Albin, F M Demotes-Mainard, J L Bouchet, G A Vincon, C Martin-Dupont.   

Abstract

We investigated the kinetics of cefotaxime in eight subjects undergoing continuous ambulatory peritoneal dialysis (CAPD). A single 1 gm iv dose was injected and a 1 gm dose was given intraperitoneally in the CAPD fluid during a 4-hour dwell time. Cefotaxime and desacetylcefotaxime were assayed by HPLC. After intravenous injection the cefotaxime serum kinetic parameters were as follows: plasma t 1/2, 2.31 +/- 0.20 hours; volume of distribution, 0.35 +/- 0.04 L/kg; total plasma clearance, 118.7 +/- 12.3 ml/min; and peritoneal clearance, 6.7 +/- 1.3 ml/min. Dialysate cefotaxime concentrations rose rapidly, but only 5% of the dose was eliminated by the peritoneal route. After intraperitoneal instillation, cefotaxime appeared in the serum rapidly and the peak serum concentrations ranged from 9 to 20 micrograms/ml between 1 and 3 hours. The absorption of cefotaxime from peritoneal space was 58.7% +/- 5.4%. Data suggest that cefotaxime has bidirectional exchange characteristics through the peritoneal membrane. Instillation of cefotaxime in CAPD fluid may permit rapid absorption to achieve therapeutic serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4028623     DOI: 10.1038/clpt.1985.172

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis.

Authors:  G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 2.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 3.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

4.  Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.

Authors:  P Somani; E H Freimer; M L Gross; J T Higgins
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

6.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Teicoplanin pharmacokinetics in patients with chronic renal failure.

Authors:  M Bonati; G L Traina; G Villa; A Salvadeo; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

8.  Pharmacokinetics of cefotaxime and its desacetyl metabolite in plasma and in cerebrospinal fluid.

Authors:  E Beyssac; J M Cardot; G Colnet; J Sirot; J M Aiache
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1987 Apr-Jun       Impact factor: 2.441

9.  Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.

Authors:  K L Heim; C E Halstenson; C M Comty; M B Affrime; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

10.  Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.

Authors:  M Bonati; G L Traina; M G Gentile; G Fellin; R Rosina; L Cavenaghi; G Buniva
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.